Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

Open access
Lantuejoul, Sylvie, Sound-Tsao, Ming, Cooper, Wendy A., Girard, Nicolas, Hirsch, Fred R., Roden, Anja C., Lopez-Rios, Fernando, Jain, Deepali, Chou, Teh-Ying, Motoi, Noriko, Kerr, Keith M., Yatabe, Yasushi, Brambilla, Elisabeth, Longshore, John, Papotti, Mauro, Sholl, Lynette M., Thunnissen, Erik, Rekhtman, Natasha, Borczuk, Alain, Bubendorf, Lukas, Minami, Yuko, Beasley, Mary Beth, Botling, Johan, Chen, Gang, Chung, Jin-Haeng, Dacic, Sanja, Hwang, David, Lin, Dongmei, Moreira, Andre, Nicholson, Andrew G., Noguchi, Masayuki, Pelosi, Giuseppe, Poleri, Claudia, Travis, William, Yoshida, Akihiko, Daigneault, Jillian B., Wistuba, Ignacio I., Mino-Kenudson, Mari·2020·Journal of Thoracic Oncology

Abstract

The recent development of immune checkpoint inhibitors (ICI) has led to promising advances in the treatment of non-small cell and small cell lung cancer patients with advanced or metastatic disease. Most of ICI target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity. Multiple clinical trials for ICI have examined a predictive value of PD-L1 protein expression in tumor cells and/or tumor-infiltrating immune cells by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms and many laboratories have set up in-house or laboratory developed tests, which are more affordable than generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in the most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging due to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. As many articles have been published since the issue of the IASLC Atlas of PD-L1 immunohistochemistry testing in lung cancer, this review by the IASLC pathology committee provides updates on the indications of ICI for lung cancer in 2019, and discusses important considerations on pre-analytical, analytical and post-analytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance and training.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.12.107

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 332

Metadata

Authors
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., Kerr, K. M., Yatabe, Y., Brambilla, E., Longshore, J., Papotti, M., Sholl, L. M., Thunnissen, E., Rekhtman, N., Borczuk, A., Bubendorf, L., Minami, Y., Beasley, M. B., Botling, J., Chen, G., Chung, J.-H., Dacic, S., Hwang, D., Lin, D., Moreira, A., Nicholson, A. G., Noguchi, M., Pelosi, G., Poleri, C., Travis, W., Yoshida, A., Daigneault, J. B., Wistuba, I. I., & Mino-Kenudson, M.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-04
Volume
15
Issue
4
Pages
499-519
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2995123342
Cited by
332
References
85
FWCI
16.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. https://app.cochat.ai/papers/10.1016/j.jtho.2019.12.107
The paper
Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., Kerr, K. M., Yatabe, Y., Brambilla, E., Longshore, J., Papotti, M., Sholl, L. M., Thunnissen, E., Rekhtman, N., Borczuk, A., . . . Mino-Kenudson, M. (2020). PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.12.107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.